Abstract 1584P
Background
The AIO-FLOT3 Trial suggested that conversion therapy might improve outcome in pts with metastatic gastric cancer (GC). We conducted this prospective, single-arm, phase II trial to improve conversion efficacy of ICIs combined with mFLOT regimen (fluorouracil, oxaliplatin, and nab-PTX) in pts with initially unresectable locally advanced or limited metastatic GC or GEJ adenocarcinoma.
Methods
Eligible pts received Cam 200mg, oxaliplatin 85 mg/m2, nab-PTX 125 mg/m2 or with trastuzumab if Her2 positive, each was an IV followed by fluorouracil 2400 mg/m2 as a 48-h continuous iv on day 1, every 2 weeks. Pts were assessed for tumor response and surgical feasibility every 3 cycles. The primary endpoint was R0 conversion rate.
Results
35 pts were enrolled up to 04/2023. 30 pts were evaluable. The median age was 50y. Male was 76.7%. The metastatic sites included liver 50.0% (15), retroperitoneal lymph nodes (LNs) 33.0% (10), axillary and supraclavicular LNs 6.7% (2), Krukenberg 3.3% (1), adrenal gland 3.3% (1), and locally advanced unresectable 10% (3). 7(23.3%) pts had two or more unresectable lesions. 4 pts were dMMR/MSI-H and 4 were Her2 positive. ORR was 86.7% and DCR was 96.7%. 25(83.3%) pts were assessed as resectable after conversion therapy. One pt refused surgery and 2 were cCR under observation. 22 pts (73.3%) received operation with R0 resection and no perioperative mortality. With 2 cCR included, R0 conversion rate was 80.0% (24/30). 5 pts (22.7%) achieved pCR and 12(54.5%) achieved MPR. Grade 3 AEs included 2 cases of rash, 1 case of adrenal insufficiency, 1 case each of ALT, AST elevation and febrile neutropenia. 1 pt was Grade 4 Neutrophil count decreased. (Table)
Table: 1584P
Response and surgical conversion, n (%) | N=30 | |
ORR | 26 (86.7) | |
CR | 2 (6.7) | |
PR | 24 (80.0) | |
DCR | 29 (96.7) | |
SD | 3 (10.0) | |
PD | 1 (3.3) | |
R0 conversion rate | 24 (80.0) | |
Pathological response | pCR | 5/22 (22.7) |
MPR | 12/22 (54.5) | |
cCR+pCR | 7 (23.3) |
Conclusions
Cam combined with mFLOT regimen safely induced a high conversion rate, with very high R0 resection, pCR and MPR. The findings warrant further prospective investigations.
Clinical trial identification
NCT04510064.
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1655P - Nampt inhibitors re-sensitize MAP17 expressing pancreas tumors
Presenter: Julia Martinez Perez
Session: Poster session 22
1656P - Targeting NPC1L1 rescues anti-tumor immunity and improves immunotherapeutic efficacy in pancreatic cancer
Presenter: Houjie Liang
Session: Poster session 22
1657P - Understanding the role of SAGA and mediator in the resistance to Pdk1 deletion in PDAC
Presenter: Katarina Ondrejkova
Session: Poster session 22
1658P - Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants
Presenter: Julie Earl
Session: Poster session 22
1659P - The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Presenter: Octave Letissier
Session: Poster session 22
1660P - Squalene epoxidase promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signalling pathway
Presenter: Ruiyuan Xu
Session: Poster session 22
1661P - Precision medicine for pancreatic cancer: A clinical study validating EUS biopsies
Presenter: Joanne Lundy
Session: Poster session 22
1662P - Targeting stress granule formation as a synthetic lethality strategy for kras-induced pancreatic cancer initiation
Presenter: Patricia Santofimia
Session: Poster session 22
1663P - Role of next-generation sequencing somatic assays in patients with advanced pancreatic cancer
Presenter: Rafaela Naves
Session: Poster session 22
1664P - Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
Presenter: Michele Reni
Session: Poster session 22